Dinesh Khanna, MD, MSc, Frederick G.L. Huetwell Professor of Rheumatology and director of the Scleroderma Program at the University of Michigan, spoke with Rheumatology Advisor about the results of the open-label portion of a trial evaluating the safety and efficacy of placebo-treated patients with systemic sclerosis who were switched to receive open-label tocilizumab (ClinicalTrials.gov Identifier: NCT01532869). 

This data was recently presented at the American College of Rheumatology annual meeting in Washington DC. 

Reference

Khanna D, Denton C, Spotswood H, Jahreis A, van Laar JM, Burke L, Lin CJF, Pope JE, Allanore Y, Müller-Ladner U, Siegel J, Furst DE. Safety and efficacy of subcutaneous tocilizumab in early systemic sclerosis: Results from the open-label period of a phase 2 randomized, controlled trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). http://acrabstracts.org/abstract/safety-and-efficacy-of-subcutaneous-tocilizumab-in-early-systemic-sclerosis-results-from-the-open-label-period-of-a-phase-2-randomized-controlled-trial/. Accessed November 21, 2016.


Continue Reading

follow @RheumAdvisor